There’s a femtech revolution and the UK is leading it

Mace | 17th June 2022 | Uncategorised

Professor Asif Ahmed tells Mace how he's leading the charge for developing new medicines to treat pre-eclampsia

Mace sat down with Professor Asif Ahmed, Executive Chairman and Founder of MirZyme, a UK-based biopharmaceutical biotech company that focuses on the development and commercialisation of tailored therapeutics to prevent pre-eclampsia, to learn more about how he is leading the femtech revolution. Mace: What is pre-eclampsia, how does it occur and whom does it affect? AA: Let me start with a personal story. A bereaved mother and retired biochemist Dr Carolyn Fahm recalls losing her child to pre-eclampsia decades ago as if it was yesterday. She told me: “I’ve been obsessed with pre-eclampsia ever since I lost my child,” she said. “At the time, I was far too ill to leave the hospital and attend to my son's funeral arrangements. Things like that leave emotional scars. They change us physically, too: The hypertension has left visibly distended cranial blood vessels that I have seen on one of my CT scans done as part of an epilepsy neurology workup. Like Covid-19, pre-eclampsia occurs without ...

Subscribe to The Mace

Join the member community shaping British politics and stay ahead of what's really happening in the world of politics and public affairs, with expert analysis, breaking news, and insider insights from Westminster and Brussels. The Mace is the leading news source and resource for the government affairs industry, offering required reading and lobby intelligence for professionals.

To see what you are missing out on by not subscribing to The Mace, click here to download our full membership info-pack. This includes having no paywall on op-ed content or profiles/interviews, allowing professional profiles to be read with maximum impact and visibility by government, special advisers, MPs, peers, civil servants, and policy and political decision-makers.